News about "GSK"

GSK to Invest USD 30 Billion in US R&D and Supply Chain Over Next 5 Years

GSK has announced plans to invest USD 30 billion across the United States over the next five years to strengthen its R&D, drug discovery, development, and clinical trial activity.

GSK | 17/09/2025 | By Dineshwori

Hengrui Pharma and GSK Partner to Develop 12 Innovative Drugs Across Respiratory, Immunology and Oncology

Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.

GSK | 28/07/2025 | By Mrinmoy Dey

Pharma Leaders Back UK Life Sciences Strategy, But ABPI Warns of Medicines Investment Gap

Pharmaceutical and medical technology leaders, including GSK, Sandoz, Accord Healthcare, Becton Dickinson, and Celltrion have welcomed the UK government’s new Life Sciences Sector Plan, recently unveiled as part of its flagship Industrial Strategy.

GSK | 19/07/2025 | By Dineshwori

GSK Secures FDA Approval for Prefilled Syringe Version of Shingles Vaccine Shingrix

GSK has received approval from the US Food and Drug Administration (FDA) for a new prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine, RZV), designed to prevent shingles (herpes zoster).

GSK | 17/07/2025 | By Dineshwori |  158

GSK Completes Acquisition of IDRx

IDRX-42 has demonstrated activity against all clinically relevant primary and secondary KIT mutations, a key medical need in current GIST treatment.

GSK | 25/02/2025 | By Aishwarya |  154

Muna Therapeutics Partners with GSK to Develop Novel Treatments for Alzheimer's Disease

Together, Muna and GSK will assess postmortem human brain samples with spatial transcriptomics and other approaches to identify and validate potential new drug targets.

GSK | 06/12/2024 | By Aishwarya |  135

GSK Announces Positive Data for Arexvy (RSV) Vaccine

Arexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older, including those who are at increased risk due to certain underlying medical conditions.

GSK | 10/10/2024 | By Aishwarya |  373

BioVersys Extends its Strategic Collaboration with GSK

BioVersys has extended its strategic collaboration with the global biopharma company GSK to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).

GSK | 09/05/2024 | By Aishwarya |  403

Pharma giant GSK to build Singapore facility making Hepatitis B vaccine

Pharma giant GSK to build Singapore facility making Hepatitis B vaccine

GSK | 14/07/2023 | By Sudeep Soparkar |  578

GSK in agreement to acquire late-stage biopharma company BELLUS Health

The acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC

GSK | 25/04/2023 | By Sudeep Soparkar |  701